Navigation
banner

The Opioid Crisis and Alternatives

2018-04-192018-04-152018-04-07
Register 3 for the price of 2 with the coupon code rcdvb!


KEYNOTE SPEAKERS
Christopher Jones

Christopher Jones
Director, National Mental Health and Substance Use Policy Laboratory
SAMHSA
Christopher Jones
Director, National Mental Health and Substance Use Policy Laboratory
SAMHSA
 
About Speaker:

Christopher M. Jones, PharmD, MPH Director, National Mental Health and Substance Use Policy Laboratory Substance Abuse and Mental Health Services Administration U.S. Department of Health and Human Services

Christopher M. Jones serves as the Director of the National Mental Health and Substance Use Policy Laboratory at the Substance Abuse and Mental Health Services Administration (SAMHSA). The Policy Lab, created in the 21st Century Cures Act, is charged with identifying, coordinating, and facilitating the implementation of policy changes likely to have a significant effect on mental health, mental illness, recovery supports, and the prevention and treatment of substance use disorders, and working to advance innovation and the dissemination and adoption of evidence-based practices and programs related to mental health and substance abuse. Prior to joining SAMHSA, Dr. Jones served as Acting Associate Deputy Assistant Secretary for Science and Data Policy and Director of the Division of Science Policy in the Office of the Assistant Secretary for Planning and Evaluation (ASPE) at the U.S. Department of Health and Human Services. The Office of Science and Data Policy is the HHS focal point for policy research, analysis, evaluation, and coordination of public health, science, and data policy activities, and provides authoritative advice and analytical support to HHS leadership on public health, science, and data policy issues and initiatives. He has also served as senior advisor in the Office of the Commissioner at the U.S. Food and Drug Administration (FDA) and led the Centers for Disease Control and Prevention’s (CDC) drug abuse and overdose activities where he focused on strategic policy development and implementation, engaging national and state partners, and conducting research to improve policy and clinical practice. During his career, Dr. Jones has served as Senior Public Health Advisor to the White House Office of National Drug Control Policy, led the FDA’s Drug Safety and Risk Communication team, and served on the Science Team in the CDC’s Strategic National Stockpile. He received his Bachelor of Science degree from Reinhart College, his Doctor of Pharmacy degree from Mercer University, his Master of Public Health degree from New York Medical College, and is currently completing his Doctorate of Public Health in Heath Policy at The George Washington University Milken Institute School of Public Health. Dr. Jones has authored more than 50 peer-reviewed publications on the topic of drug abuse and overdose.

Walter Ling

Walter Ling
Professor, Psychiatry; Founding Director, Integrated Substance Abuse Programs (ISAP)
UCLA
Walter Ling
Professor, Psychiatry; Founding Director, Integrated Substance Abuse Programs (ISAP)
UCLA
 
About Speaker:

Walter Ling MD is Professor Emeritus of Psychiatry and the founding director of the Integrated Substance Abuse Programs (ISAP) at UCLA. He is board certified in both neurology and psychiatry and has enjoyed a successful career in research and practice for more than five decades, consistently listed in the Best Doctors in American and Best Doctors in the West. Dr. Ling’s research has contributed pivotal data to the Food and Drugs Administration’s approval of all the currently available medications in Medication Assisted Treatment—methadone, buprenorphine, and naltrexone.  

Respected nationally and internationally as clinician, researcher, and teacher, Dr. Ling has served as consultant on narcotic affairs to the US Department of State, the World Health Organization, and United Nation’s Office of Drug Control. Under his leadership, the UCLA Integrated Substance Abuse Programs has provided extensive drug abuse training in the last 20 years to countries in Asia, Southeast Asia, and the Middle East.

Dr. Ling is the author of the highly acclaimed book “Mastering the Addicted Brain”.

DISTINGUISHED SPEAKERS
Edward Bilsky

Edward Bilsky
Provost & Chief Academic Officer
Pacific Northwest University of Health Sciences
Edward Bilsky
Provost & Chief Academic Officer
Pacific Northwest University of Health Sciences
 
About Speaker:

Dr. Edward Bilsky currently serves as the Provost and Chief Academic Office at Pacific Northwest University (PMWU). He received a Ph.D. in Pharmacology and Toxicology from the University of Arizona Colleges of Medicine and Pharmacy in 1996, with a concentration in opioid pharmacology, pain and addiction.

As an assistant professor at the University of Northern Colorado, he received that institutions highest honor, the Faculty Member of the Year in the spring of 2001, for his outstanding teaching, research and service to students. In the fall of 2001, he joined the faculty at the University of New England where he became a tenured Professor of Pharmacology and was the founding Director of the Center of Excellence in Neuroscience (CEN). Under his leadership, the CEN incorporated research, education and outreach into its mission and vision and has created a robust community of neuroscientists who are making meaningful contributions to their discipline, institution and community. He served as the Vice President for Research and Scholarship at UNE from 2011-2016. Under his leadership, UNE substantially grew the amount of external funding and scholarly output of the faculty and students, including major NIH and other health-related grants.

Dr. Bilsky engages a broad group of audiences on a variety of topics related to the neurobiology of pain, pain management and addiction to students in colleges of Osteopathic Medicine, Dental Medicine, Health Professions, Arts and Sciences and Pharmacy. He was awarded the 2011 AOA Research Mentor of the Year Award, was a finalist for the 2014 Council on Undergraduate Research Fellows award, a recipient of the Faculty for Undergraduate Neuroscience Lifetime Achievement Award and the 2014 Patient Advocacy Award from the American Academy of Pain Medicine. Dr. Bilsky's laboratory conducts translational research in the areas of pain, addiction and other neurological disorders. He has received over 6 million dollars in extramural funding to his own laboratory through a variety of federal, state and private grants and contracts including the National Institutes of Health, the Office of Naval Research and biotechnology/pharmaceutical companies. He has published over 80 peer-reviewed publications in leading journals, and has presented nationally and internationally in a variety of different venues. Dr. Bilsky co-founded two biotechnology companies that developed novel analgesics and other drugs to help manage opioid side effects. Part of this work brought a novel opioid antagonist into clinical trials. Both companies received SBIR phase I and II funding, and Dr. Bilsky has reviewed SBIRs and U grants for NIH study sections.

As an expert in opioid pharmacology and early-stage drug discovery and development, he collaborates with scientists around the world and frequently consults and conducts contracted work with biotechnology and pharmaceutical companies that have programs in analgesia and pain medicine. He is also an engaged advocate for funding the National Institutes of Health and engaging and educating the public on important topics of science and medicine.

Catherine Cahill

Catherine Cahill
Professor, Psychiatry & Biobehavioral Sciences
UCLA
Catherine Cahill
Professor, Psychiatry & Biobehavioral Sciences
UCLA
 
About Speaker:

Dr. Cahill is an opioid neuropharmacologist studying mechanisms of chronic pain and opioid analgesia, tolerance, dependence and addiction. Her research encompasses both translational basic science and clinical studies, which is supported by government agencies, pharmaceutical companies and philanthropy. She received her BSc in Chemistry in 1987 from Mount Allison University, New Brunswick, Canada and a MSc (1992) and PhD (1996) in Pharmacology from Dalhousie University, Nova Scotia, Canada. She completed postdoctoral training in the Department of Neurology & Neurosurgery at the Montreal Neurological Institute and at the Clinical institute of Montreal prior to her first faculty position in Pharmacology & Anesthesiology at Queen’s University, Ontario, Canada in 1992. She is currently a professor in the Department of Psychiatry & Biobehavioral Sciences within the Semel Institute for Neuroscience and Human Behavior at UCLA. As a testament to her recognition as a leader in her field, Dr. Cahill has given more than 80 national and international conference lectures and academic institutions as well as being actively involved in various neuroscience outreach programs. She is currently a member of the executive council for International Narcotic Research Conference and a member of the Hatos Center for Neuropharmacology. She has received many prestigious awards including the Hugill Anaesthesiology Award and held a Canada Research Chair in Chronic Pain for 10 years before moving to California.

Christopher Evans

Christopher Evans
Director, Brain Research Institute; Professor, Psychiatry and Biobehavioral Sciences
UCLA
Christopher Evans
Director, Brain Research Institute; Professor, Psychiatry and Biobehavioral Sciences
UCLA
 
About Speaker:

Dr. Evans is a Professor in the departments of Psychiatry and Psychology at UCLA and holds the Stefan Hatos Chair for Neuropharmacology in the UCLA Semel Institute for Neuroscience and Human Behavior. He received his Ph.D. in peptide chemistry from the Medical Research Council institute and Imperial College in the UK working on enkephalin analogues and endogenous opioid precursor processing. Dr. Evans completed his postdoctoral training at Stanford University with Dr. Jack Barchas and then moved to UCLA where he has continued his research on the opioid system. Dr. Evans is currently director of the Center for Opioid Receptors and Drugs of Abuse (CSORDA) at UCLA. Prior research from CSORDA has included the identification and characterization of novel endogenous opioids, the cloning of the first opioid receptor and the early studies demonstrating opioid agonist bias. Recent research has focused on the circuits that sustain opioid reward-related behaviors including place preference and opiate self-administration using a combination of mouse genetics, cell biology and pharmacology. In the light of the high co-morbidity of opioid use disorders with psychiatric disorders such as depression, anxiety and PTSD, his current research is focusing on the pathways and allostatic changes that are mediating the negative affect induced both during opioid abstinence and chronic pain states. The premise of the research is that a learned relief of negative affect by opioid drugs plays a key role in both drug craving and relapse which is articulated in a recent review published in Faculty 1000 (PMC4955026).

Fauad Hasan

Fauad Hasan
President & CEO
Bonti
Fauad Hasan
President & CEO
Bonti
 
About Speaker:

A chemical engineer, with graduate degrees from University of Maryland, including MBA, Fauad comes with more than 17 years of experience in the Biopharmaceutical industry, Fauad Hasan is the President and CEO of Bonti, Inc. Until recently, he was the strategic and technical leader in R&D group at Allergan, where he also served on the Global Product Development teams of top tier neurotoxins and ocular programs establishing overall drug development strategy from discovery to commercialization. This include taking next generation Botox® molecules and ophthalmic drugs such as DARPin® through their product life cycle from proof of concept stage through late stage development and interaction with global regulatory agencies. 

At Allergan his responsibilities also included establishing strategic planning and operations function, which included forming partnerships with external partners focusing on biologic development and manufacturing activities.  He has also been involved in performing due-diligence exercise, evaluating companies and technologies that fits Allergan’s business model.

Fauad started his career at Regeneron Pharmaceuticals, where he was part of the group that developed manufacturing processes for IL and VEGF-Trap molecules, including Eylea ($1.5B drug for AMD and DME).  He moved on to Baxter International working in various roles of increasing responsibilities in the areas of process development, manufacturing, plant engineering, and project management, catering to both internal and external client projects for therapeutic proteins, that included Mabs, in addition to blood clotting proteins (FVIII and FIX). Fauad is one of the pioneers of Single-use bioreactor (SUB) for the production of therapeutic proteins.  He is a co-owner of several patents related to this technology.  

Mireille Jacobson

Mireille Jacobson
Associate Professor, The Paul Merage School of Business; Director, Center for Health Care Management and Policy
UC Irvine
Mireille Jacobson
Associate Professor, The Paul Merage School of Business; Director, Center for Health Care Management and Policy
UC Irvine
 
About Speaker:

Mireille Jacobson is an associate professor of economics and public policy and the Director of the Center for Health Care Management and Policy at The Merage School of Business at the University of California, Irvine. She is also a research associate in the Health Care program at the National Bureau of Economic Research. She has a diverse portfolio of research united by an interest in understanding how health care policies affect well-being. Professor Jacobson received her B.A. in economics from the University of Chicago and her Ph.D., also in economics, from Harvard University.

Anthony Okorodudu

Anthony Okorodudu
Professor, Pathology
University of Texas Medical Branch
Anthony Okorodudu
Professor, Pathology
University of Texas Medical Branch
 
About Speaker:

Anthony O. Okorodudu, PhD, MBA, DABCC, FACB

Professor Anthony O. Okorodudu obtained his doctorate degree in Pathology (1982; University of Medicine and Dentistry of New Jersey) following an undergraduate degree from Rutgers University. He also holds an MS degree in Management, Computing, and Systems (Houston Baptist University), MBA degree (Rice University), and completed his fellowship training in Clinical Chemistry at Hartford Hospital in Hartford, CT. Professor Okorodudu is a Diplomate of the American Board of Clinical Chemistry and a Fellow of National Academy of Clinical Biochemistry.

His professional career includes service as Lecturer I at the Department of Chemical Pathology, School of Medicine, University of Benin (1982-1986), and Immunochemist/Fellow, Clinical Chemistry Division, Hartford Hospital, CT (1986-1988). Since 1989, he has been with the University of Texas System (UTMB), where he is Professor of Pathology and Director of Clinical Chemistry Division for UTMB Hospitals and Correctional Clinical Laboratories for UTMB/Texas Department of Criminal Justice, Pathology Clients Services Division, ComACC-Accredited Postdoctoral Training Program in Clinical Chemistry, and Pathology Residents Training in Clinical Chemistry. He is also on the faculty of the UTMB Graduate School of Biomedical Sciences where he has supervised the PhD dissertations for several students (including one from University of Benin). He has published extensively with more than 100 peer-reviewed papers, several book chapters, and over 100 abstracts. His research focus is in the elucidation of the pathophysiology of intracellular ions in the pathology of drug-drug interactions.

Professor Okorodudu is very active in his professional associations at the national level where he served on the AACC Board of Directors from 2002 – 2006. He also served the International Federation of Clinical Chemistry as Chair of the Committee on Point of Care Testing. His other international professional involvements include current and immediate past service as reviewer for several medical/scientific journals and service on the Board of Editors for the following journals: Clinical Lab News, Clin Chim Acta, POCT, Journal of Pediatric Biochemistry, and Open Clinical Chemistry. His professional accomplishments have been widely recognized with awards that include the “2001 Distinguished Alumni Award” from the Graduate School of Biomedical Sciences, University of Medicine and Dentistry of New Jersey. He is also the recipient of the “Role Model Award” from Minority Access, Inc. (in cooperation with the Office of Minority Health, National Institute of Health), AACC International Travel Award, and the TX AACC Clinical Chemist Award.

Together with his wife, Osato, they have four children and eight grandchildren.

Steven Passik

Steven Passik
Vice President, Scientific Affairs, Education & Policy
Collegium Pharmaceutical
Steven Passik
Vice President, Scientific Affairs, Education & Policy
Collegium Pharmaceutical
 
About Speaker:
Marlies Perez

Marlies Perez
Division Chief
California Department of Health Care Services
Marlies Perez
Division Chief
California Department of Health Care Services
 
About Speaker:

Marlies L. Perez is the Division Chief over the Substance Use Disorder (SUD) Compliance Division within the Department of Health Care Services.  Ms. Perez oversees the SUD licensing and certification, monitoring, and complaints for Driving Under the Influence Programs, Narcotic Treatment Programs, and outpatient and residential providers.  The Division is also responsible for implementing the Drug Medi-Cal Organized Delivery System 1115 waiver, SAMHSA Opioid STR grant and oversight of counselor certification.  Ms. Perez has worked in the SUD treatment field for over seventeen years; since the inception of Proposition 36.  Her other experience includes the California Conservation Corps, president of a non-profit service organization, VISTA Volunteer, and authoring fiction novels.  Ms. Perez has a Bachelor’s degree in International Relations and a Master’s degree in Organizational Management.

Daniele Piomelli

Daniele Piomelli
Professor, Anatomy & Neurobiology
UC Irvine
Daniele Piomelli
Professor, Anatomy & Neurobiology
UC Irvine
 
About Speaker:
Otto Schalk

Otto Schalk
Prosecuting Attorney
Harrison County, Indiana
Otto Schalk
Prosecuting Attorney
Harrison County, Indiana
 
About Speaker:

Harrison County Prosecutor, J. Otto Schalk, received his undergraduate degree in Business Marketing from the University of Kentucky and his law degree from the University Of Dayton School Of Law. Elected as Prosecuting Attorney at age 25, Schalk was reported to be one of the youngest prosecutors ever elected in the State of Indiana. Since assuming office, Schalk has prosecuted numerous murder cases, includes multiple capital cases. His experience ranges from driving under the influence cases to a variety of property crime, arson, general assault, sexual assault, child abuse prosecutions. Recognizing the dire need for effective education regarding opiate abuse, Schalk produced A Hit of Hell, which highlights the devastating effects of opioids and heroin use. The documentary has received national attention and has been shown to several schools throughout Indiana. Schalk lives in Corydon, Indiana with his wife, Allison, and their 3 children.

Michael Schatman

Michael Schatman
Adjunct Clinical Assistant Professor, Public Health & Community Medicine
Tufts University School of Medicine
Michael Schatman
Adjunct Clinical Assistant Professor, Public Health & Community Medicine
Tufts University School of Medicine
 
About Speaker:

Dr. Schatman is a clinical psychologist who has spent the past 32 years working in multidisciplinary chronic pain management. He is currently on the teaching faculty of the Department of Public Health & Community Medicine at the Tufts University School of Medicine, and serves as Director of Research and Network Development for Boston Pain Care in Waltham, MA. Dr. Schatman is the author of over 100 journal articles and book chapters on various aspects of chronic pain management, and lectures regularly on pain management on local, national and international bases. He is also the editor of Ethical Issues in Chronic Pain Management and Chronic Pain Management: Guidelines for Multidisciplinary Program Development, both of which were released by Informa Healthcare in 2007. Dr. Schatman is a member of the Editorial Boards of numerous journals. For the past 5 years, he has served as the Editor-in-Chief of the Journal of Pain Research. He is the past-Chairperson of the Ethics Special Interest Group of the American Pain Society, is a member of the Ethics Committee of the American Pain Society, the Ethics Council of the American Academy of Pain Medicine, and is on the Board of Directors of the American Society of Pain Educators – which named him 2011 Clinical Pain Educator of the Year.

Gary Tsai

Gary Tsai
Medical Director & Science Officer, Substance Abuse Prevention and Control
Los Angeles County Department of Public Health
Gary Tsai
Medical Director & Science Officer, Substance Abuse Prevention and Control
Los Angeles County Department of Public Health
 
About Speaker:

Gary Tsai, M.D. is the Medical Director and Science Officer for the Substance Abuse Prevention and Control, a division of the Los Angeles County Department of Public Health. He is board certified in both general adult psychiatry and addiction medicine, and continues clinical practice at Cedars-Sinai Medical Center. Having experienced the stigma and criminalization that often accompanies serious mental illness as the son of a mother with schizophrenia, Dr. Tsai is a passionate advocate for improving our behavioral health systems. In his pursuit of meaningful change, Dr. Tsai is also the founder of Forgotten Films, a film production company focusing on social issue projects, specializing in behavioral health. Its first film, Voices, premiered on public television in May 2015 for Mental Health Awareness Month and was awarded a 2016 SAMHSA Voice Award, Honorable Mention.

Bob Twillman

Bob Twillman
Executive Director
Academy of Integrative Pain Management
Bob Twillman
Executive Director
Academy of Integrative Pain Management
 
About Speaker:

Bob Twillman, Ph.D., is the Executive Director of the Academy of Integrative Pain Management (formerly the American Academy of Pain Management). In that capacity, Dr. Twillman is responsible for guiding the organization in its efforts to promote an integrative approach to managing pain. He formerly served the Academy for four years as its Director of Policy and Advocacy. Dr. Twillman received his Ph.D. in Clinical Psychology at the University of California in Los Angeles, and maintains a volunteer faculty appointment as Clinical Associate Professor of Psychiatry and Behavioral Sciences at the University Of Kansas School Of Medicine in Kansas City, KS. Prior to working for the Academy, Dr. Twillman was a full-time faculty member at the University of Kansas Medical Center, where he founded and directed the inpatient pain management program and was a co-founder of the hospital’s Palliative Care Team. Dr. Twillman also served for many years as Chair of the Prescription Monitoring Program Advisory Committee for the Kansas Board of Pharmacy.

Elizabeth Whalley Buono

Elizabeth Whalley Buono
Practice Head, Process & Innovation Management
Kinexum
Elizabeth Whalley Buono
Practice Head, Process & Innovation Management
Kinexum
 
About Speaker:

Liz Whalley Buono provides Life Sciences, Fraud & Abuse, Healthcare Innovation & New Product Development legal and regulatory support to a broad array of healthcare clients as a Director at HDJN, LLC. Liz began her legal career in 2001 at Wiley, Rein and Fielding, LLP in Washington, DC, where she supported consumer product, pharmaceutical, biotech and device firms on a wide range of federal and state regulatory issues. Prior to practicing law, she had careers as a medical/surgical and psychiatric nurse in the Boston area and had an extensive 13-year tenure in the pharmaceutical industry with Parke-Davis/Warner Lambert and Pfizer. In 2003, Liz joined Altria Client Services as Regulatory and Senior Counsel, managing the legal and health ethics considerations associated with clinical research and new product development activities undertaken in pursuit of tobacco harm reduction. In 2009, Liz moved to MPS / WestRock Healthcare as V.P., Global Quality, Regulatory and External Affairs and General Counsel for the company’s Healthcare division with primary responsibility for ensuring compliance and creating competitive advantage for the company’s patient medication adherence products and services. Liz continues to provide that support to WestRock Healthcare in a secunded role. More recently, through her private consultancy, Liz supported healthcare innovation efforts undertaken by, among others, the Bill and Melinda Gates Foundation, the Arcady Group, Novartis and Kinexum, LLC. She currently serves on the FDA Working Group to Enhance Opioid Safety and the CDC PROTECT Initiative.

Liz received her BSN from Boston College School of Nursing and earned her MBA in Executive Management from St. John’s University College of Business Administration. She received her JD in Health Law and Economics from George Mason University.